Navigation Links
Cognitive rehabilitation holds promise for schizophrenic brain function improvements

Study had shown that it is possible to improve the brain functions of schizophrenic// patients through cognitive rehabilitation programs.

Researchers from Washington University in St. Louis have suggested that memorization strategies used by normal people to remember things may be useful for schizophrenia patients as much in remembering information. This process may also start the return of normalcy in remembering and retaining information in the brain by these people suffering from the disease.

Schizophrenia is a chronic severe disabling mental illness. Some of the symptoms suffered by schizophrenics are hallucinations seen or heard, feelings of being persecuted, becoming withdrawn, aggression and deranged behavior. Schizophrenia can be treated symptomatically, but only one in five patients have a chance of full recovery. However, other than the severe problems associated with the disease, the disease is also associated with learning, memory, attention related problems that hamper the daily life of the patients.

The study suggests that the use of helpful memory strategies through cognitive rehabilitation programs that improve the cognitive abilities of the patients can go a long way in improving the functions of the brain of these patients.

Reference: Biological Psychiatry, July 2005
'"/>




Page: 1

Related medicine news :

1. Women With Diabetes At Increased Risk Of Developing Cognitive Impairment
2. Physical Activity Good For Developing Cognitive Skills
3. Suicidal Tendencies May Be Treated With Cognitive Therapy
4. Blood Pressure Later Leads to Cognitive Problems
5. Cognitive Behavioral Therapy Seen To Be Effective Against Back Pain
6. Anticholinergic Medicines Result In Cognitive Impairment
7. Cognitive deterioration in the older generation can be prevented by modifying the lifestyle
8. Fetal Neural Grafts Improves Motor and Cognitive Function in Huntington Patients
9. High Blood Pressure Leads to Rusting of Cognitive Skills
10. Older Women Who Are Avid Watchers of the Tube Have Cognitive Difficulties
11. Cognitive Impairment or Dementia Risk, Pronounced with Ovary loss
Post Your Comments:
(Date:7/25/2008)... Authority offers patients consumers tips and enco...nt safety, HARRISBURG, Pa., July 25 /PRNewswire-U...ority today supports "National Patient Safety Day"...and their families to,participate fully in their h...ing they can about their surgery or illness., "We...
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begin...l/ -- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ...ced today that its subsidiary has commenced commer...psules USP product in the 40mg,strength from its D...on,with the launch, Watson has 180 days of marketi...
(Date:7/25/2008)...ck to benefit ALS Therapy Alliance to be presented...ight, WOONSOCKET, R.I., July 25 /PRNewswire/ -- C...raised a record-breaking $4.4 million in just 21 d...gn for ALS research. This is,the seventh year of t...aised more than $15 million for ALS research. This...
(Date:7/25/2008)... The Retina Group of New York wi...lated macular degeneration especially designed for...ale Public Library at 116 Merritts Road, Farmingda...15. Attendance is free and refreshments will be pr...516) 939-6100. , Hicksvil...
Breaking Medicine News(10 mins):Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3
...ined that the deadly Human Immune Deficiency Virus...accine used in Africa in the 1950s and say rumours...ce to back them up. The studies, from researchers ...d help free the polio vaccine manufactured by the ...
... most painful and bothering one is the trauma of g... according to many diabetics is the finger stick. ...p to six times a day for more than ten to twenty y...he pain and discomfort associated with them. But r...
...hursday that plans are afoot to consider listing o...n the US bourses after 2002," Pratap C Reddy, chai... was a part of the business plan for the post-2002...available at the moment, Dr. Reddy added that plan...
... can be prevented if the patients and their doctor...ng to WHO, around 150 million people suffer from a...o the disease every year. Asthma is a chronic resp...t is characterized by sudden recurring attacks of ...
Other Medicine News:
(Date:7/24/2008)...-FirstCall/ -- Alexza,Pharmaceuticals, Inc. (Nasda...ts second Phase 3 clinical trial with AZ-004 (Stac... candidate being developed for the treatment,of ac...polar disorder.,Alexza believes the novel, non-inv...ties resulting from inhaled loxapine administratio...
(Date:7/24/2008).../ -- Headlines claiming "soy,products lower sperm ...e,preliminary study that Dr. Jorge Chavarro, publ...collected intake of soyfoods and not on,specific d...d by many,issues, thus I feel the results should b... Tammy Hedlund, a researcher in prostate cancer,pr...
(Date:7/24/2008)... body temperature, for home,and clinical use, WES...-Med, Inc.,(subsidiary of American Scientific Reso...ibutor of the Thermofocus(R) 5-in-1 non-contact,th... clinical study,conducted by the Second Children,s...y, which proves that the Thermofocus(R) measures b...
(Date:7/24/2008)...ire-FirstCall/ -- NicOx S.A.,(Euronext Paris: COX)...week,open label safety extension that was conducte...y for naproxcinod. The results revealed no unexpec...r the one-year duration of,the study, as measured ...ion, the results showed that the patients, mean bl...
Breaking Medicine Technology:Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Soyfoods Do Not Impact Sperm Count 2Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Armed beetles find a mate whatever their size 2646 1Small Business Health Care Survey Points to Need for Reform 15325 1Small Business Health Care Survey Points to Need for Reform 15325 2Clarient to Present at the B Riley 26 Co 9th Annual Las Vegas Investor Conference 15320 1Clarient to Present at the B Riley 26 Co 9th Annual Las Vegas Investor Conference 15320 2Patient Experience Expert to Present The Power of Wow 21 in Health Care Service Delivery 4227 1Patient Experience Expert to Present The Power of Wow 21 in Health Care Service Delivery 4227 2
...PRNewswire/ -- Asenapine -- an,investigational dru... business unit of Akzo Nobel, for bipolar I disord...e effective than placebo,in treating acute manic a...er, according to new Phase III results, from a stu...on,s 2007 Annual,Meeting. , In the three-week stud...
...ent Reduction in Risk of Hospitalization,from Croh...Ill., May 22, 2007 /PRNewswire-FirstCall/ -- Abbot... of a pivotal study,presented at the Digestive Dis...ng patients with moderate to severely active,Crohn...ntenance,therapy were almost 60 percent less likel...
Other Medicine Technology:Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 2New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 3New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 4New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 5New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 6New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 7
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
Medicine Products: